Irinotecan in Treating Patients With Refractory Solid Tumors and Liver Dysfunction

Completed · Phase 1

Conditions studied: Unspecified Adult Solid Tumor, Chemotherapy, Liver Dysfunction, Neoplasms, Solid Tumor

In brief

Drugs used in chemotherapy us different ways to stop tumor cells from dividing so they stop growing or die. Irinotecan may be effective in treating patients with refractory solid tumors and liver dysfunction.

Key facts

Study ID

NCT00037804

Run by

Pfizer

Last updated by the study team

2009-08-14

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Research Center — Detroit, Michigan, United States
• Research Center — New Brunswick, New Jersey, United States
• Research Center — Nashville, Tennessee, United States
• Research Center — Marshfield, Wisconsin, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.